Sunitinib
- Generic Name
- Sunitinib
- Brand Names
- Sutent, Sunitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27FN4O2
- CAS Number
- 557795-19-4
- Unique Ingredient Identifier
- V99T50803M
- Background
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formul...
- Indication
Sunitinib is indicated for the following conditions:
- Associated Conditions
- Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
- Associated Therapies
- -
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
- Conditions
- Interventions
- First Posted Date
- 2017-08-24
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 129
- Registration Number
- NCT03260894
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇨🇦Sunnybrook Health Sciences, Odette Cancer Centre, Toronto, Ontario, Canada
Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 66
- Registration Number
- NCT03170180
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.
- Conditions
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 77
- Registration Number
- NCT03140176
- Locations
- 🇩🇿
Pierre Et Marie Curie Center, Algers, Algeria
🇩🇿Hanene Djedi, Annaba, Algeria
🇪🇬Demerdash Hospital, Cairo, Egypt
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 701
- Registration Number
- NCT03141177
- Locations
- 🇪🇸
Local Institution - 0125, Barcelona, Spain
🇪🇸Local Institution - 0121, Madrid, Spain
🇦🇺Local Institution - 0001, Southport, Queensland, Australia
Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Duke University
- Target Recruit Count
- 7
- Registration Number
- NCT03109015
- Locations
- 🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States
Savolitinib vs. Sunitinib in MET-driven PRCC.
- Conditions
- Interventions
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT03091192
- Locations
- 🇺🇦
Research Site, Sumy, Ukraine
Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.
- First Posted Date
- 2017-02-28
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Spanish Oncology Genito-Urinary Group
- Target Recruit Count
- 23
- Registration Number
- NCT03066427
- Locations
- 🇪🇸
Hospital Clínic i Provincial de Barcelona, Barcelona, Spain
🇪🇸Hospital Ramón Y Cajal, Madrid, Spain
🇪🇸Centro Integral Oncologico Clara Campal, Madrid, Spain
Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-01-30
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- Guru Sonpavde
- Registration Number
- NCT03035630
- Locations
- 🇺🇸
University of Alabama Hematology Oncology Clinic at Medical West, Birmingham, Alabama, United States
A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme
- Conditions
- Interventions
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 100
- Registration Number
- NCT03025893
- Locations
- 🇳🇱
VU University Medical Center, Amsterdam, Netherlands
🇳🇱Radboud UMC, Nijmegen, Netherlands
🇳🇱University Medical Center Groningen, Groningen, Netherlands
A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-11-10
- Last Posted Date
- 2021-04-26
- Target Recruit Count
- 200
- Registration Number
- NCT02960906
- Locations
- 🇫🇷
Centre Francois Baclesse, Caen, France
🇫🇷Hôpital Cochin, Paris, France
🇫🇷Centre Antoine Lacassagne, Nice, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.